Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.

Helicobacter pylori exposure reduces eosinophilic esophagitis risk

03 Feb 2019

Exposure to Helicobacter pylori appears to lower the risk of eosinophilic oesophagitis (EoE), according to a study. 

Researchers searched four large databases for comparative clinical studies with sufficient data to estimate the odds or risk of EoE (primary outcome) or oesophageal eosinophilia (secondary outcome) among individuals exposed to H. pylori (exposed) vs those who were tested negatively.

The meta-analysis included 11 observational studies involving 377,795 individuals worldwide. Data were pooled using random-effects model. Meta-regression and sensitivity analyses were planned a priori. Studies were individually assessed for quality, risk of bias, publication bias and heterogeneity.

Estimates showed that compared with nonexposure, H. pylori exposure was associated with a >30-percent decrease in the odds of EoE (odds ratio [OR], 0.63; 95 percent CI, 0.51–0.78) and of oesophageal eosinophilia (OR, 0.62; 0.52–0.76).

There were fewer prospective vs retrospective studies that reported a significant relationship between H. pylori exposure and EoE (p=0.06). Effect estimates were not altered by study location, whether the studies were conducted in paediatric or adult populations, time period (before vs after 2007), or prevalence of H. pylori in the study population.

Evidence has reported that previous or current infection with H. pylori protects against EoE, potentially due to infection-induced immunomodulation, researchers said. The present data lend support to this evidence, although more research is needed to determine the mechanisms of such a benefit.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.